reports
Avivagen Inc. CEO, Kym Anthony, Joins The Stock Day Podcast to Discuss...
Phoenix, Arizona--(Newsfile Corp. - October 2, 2019) - The Stock Day Podcast welcomed Avivagen Inc. (CHEXF) ("the Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. CEO of Avivagen Inc., Kym Anthony, joined Stock Day host Everett Jolly. To begin the interview, Jolly noted the Company's growing revenues over the last few quarters. "We've had a couple of major breakthroughs and we should see that reflected in sales and t...
1 director maiden bought
A director at Avivagen Inc maiden bought 50,000 shares at 0.578USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
- GlobalData Healthcare Department
Avivagen Inc (VIV) - Pharmaceuticals & Healthcare - Deals and Alliance...
Summary Avivagen Inc (Avivagen), formerly Chemaphor Inc is a biotechnology company that offers drug development and animal healthcare products. The company develops science-based, natural health products for animals. It operates through divisions including companion animal health, food animal health and human health. Avivagen’s products comprise OxC-beta and oximunol. Avivagen’s OxC-beta is an active ingredient used to support the innate immune system and a healthy inflammatory condition of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.